Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions.

Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions. Expert Opin Drug Saf. 2020 Nov 12;: Authors: Galli M, Capodanno D, Andreotti F, Crea F, Angiolillo DJ Abstract Introduction: Antiplatelet therapy represents a key strategy for the prevention of thrombotic complications in patients with both acute (ACS) and chronic coronary syndromes (CCS), particularly those undergoing percutaneous coronary intervention (PCI). In these, dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is crucial in preventing ischemic events, especially stent thrombosis. Nevertheless, DAPT is associated with a bleeding risk proportionate to its duration. Ever growing appreciation of the prognostic implications associated with bleeding and the development of safer stent platforms over the past years have led to a number of novel antiplatelet treatment strategies being tested among patients undergoing PCI. Areas covered: P2Y12 inhibitor monotherapy after a short course DAPT has emerged as a bleeding reduction strategy to mitigate such risk while still preventing thrombotic complications. In this review we describe the latest evidence regarding the safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing PCI in different clinical settings. Expert opinion: P2Y12 inhibitor monotherapy after a brief period of DAPT, generally 1 to 3 months, has emerged as an effective approach to...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research